Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 130018-87-0] Levocetirizine dihydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-W010841
Brand:	MCE
CAS:	130018-87-0

Overview

MDL	MFCD07366507
Molecular Weight	461.81
Molecular Formula	C21H27Cl3N2O3
SMILES	O=C(O)COCCN1CCN([C@@H](C2=CC=C(Cl)C=C2)C3=CC=CC=C3)CC1.[H]Cl.[H]Cl

For research use only. We do not sell to patients.

Summary

Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria ^[1] .

In Vivo

Levocetirizine (0.4 mg/kg; oral administration; male Sprague-Dawley rats) treatment shows that the C _max , AUC _0-t , AUC _0-∞ and t _1/2 are 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively in Sprague-Dawley rats ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	30 male Sprague-Dawley rats (8 weeks old; 200-250 g) ^[1]
Dosage:	0.4 mg/kg
Administration:	Oral administration (Pharmacokinetic Analysis)
Result:	The C _max , AUC _0-t , AUC _0-∞ and t _1/2 were 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00160680	UCB S.A. - Pharma Sector\|UCB Pharma	Rhinitis, Allergic, Perennial	March 1, 2005	Phase 4
NCT00521131	UCB Pharma	Rhinitis\|Allergic\|Perennial	September 2002	Phase 4
NCT00525382	UCB Pharma	Urticaria	August 2003	Phase 3
NCT00521170	UCB Pharma	Allergy	November 2004	Phase 1
NCT03590912	Lumbini Medical College	Otitis Media With Effusion	September 5, 2018	Phase 4
NCT04699604	Children´s Mercy Hospital Kansas City\|National Institutes of Health (NIH)	Allergic Asthma	April 28, 2021	Phase 3
NCT01430260	Handok Inc.\|Takeda	Allergic Rhinitis	January 2011	Phase 4
NCT00359138	Organon and Co	Hypersensitivity	February 2006	Phase 4
NCT00542607	UCB Pharma	Rhinitis, Allergic, Seasonal	September 2002	Phase 4
NCT00160537	UCB Pharma	Seasonal Allergic Rhinitis	May 2005	Phase 4
NCT00439712	Institut für Atemwegsforschung GmbH\|UCB Pharma	Perennial Allergic Rhinitis	February 2007	Phase 4
NCT01722162	Washington University School of Medicine	Colorectal Neoplasms	April 2013	Phase 2
NCT00355771	Institut für Atemwegsforschung GmbH\|UCB Pharma	Allergic Rhinitis	June 2006	Phase 4
NCT01250652	Association Asthma, Bulgaria\|UCB Pharma	Chronic Urticaria	March 2011	Phase 4
NCT00544388	UCB Pharma	Rhinitis, Allergic, Seasonal	April 2004	Phase 3
NCT00291642	UCB Pharma	Rhinitis\|Allergic\|Seasonal	January 1, 2006	Phase 2
NCT01392859	Children´s Mercy Hospital Kansas City	Asthma\|Allergic Asthma\|Non-allergic Asthma	June 2011	Phase 2\|Phase 3
NCT01008592	Wake Forest University\|UCB Pharma\|Wake Forest University Health Sciences	Rhinitis\|Urticaria	April 2009
NCT00264303	UCB Pharma	Chronic Idiopathic Urticaria	December 2005	Phase 4
NCT00621959	UCB Pharma	Seasonal Allergic Rhinitis	March 2008	Phase 4
NCT00295022	UCB S.A. - Pharma Sector\|UCB Pharma	Rhinitis, Allergic, Seasonal	July 29, 2006	Phase 4
NCT02507635	Iuliu Hatieganu University of Medicine and Pharmacy	Allergic Rhinitis	February 2009	Phase 4
NCT00520754	UCB Pharma	Cough	December 2001	Phase 2
NCT00619801	UCB Pharma	Allergic Rhinitis\|Chronic Urticaria	March 2008	Phase 3
NCT01563081	GlaxoSmithKline	Rhinitis	April 2012	Phase 3
NCT01557439	IPCA Laboratories Ltd.	Fasting State	February 2012	Phase 1
NCT03371849	Hanmi Pharmaceutical Company Limited	Healthy	July 19, 2017	Phase 1
NCT01445262	GlaxoSmithKline	Rhinitis, Allergic, Perennial and Seasonal	February 2011
NCT00160563	UCB Pharma	Asthma	June 2004	Phase 3
NCT03545464	Assistance Publique - Hôpitaux de Paris	Urticaria\|Angi?dema	September 21, 2019	Phase 3
NCT00160589	UCB Pharma	Rhinitis, Allergic, Perennial	April 2005	Phase 4
NCT00524836	UCB Pharma	Rhinitis\|Allergic\|Perennial	September 2003	Phase 3
NCT00152412	UCB Pharma	Allergic Rhinitis	June 2004	Phase 2
NCT03555890	GlaxoSmithKline\|Zensei Pharmaceutical Co., Ltd.	Rhinitis	May 18, 2018	Phase 1
NCT01062139	HK inno.N Corporation	Perennial Allergic Rhinitis	October 2009	Phase 4
NCT01509209	Hanmi Pharmaceutical Company Limited	Vasomotor Rhinitis	May 2011	Phase 3
NCT00679250	Brian J Lipworth\|University of Dundee	Allergic Rhinitis	November 2005	Phase 4
NCT00152464	UCB Pharma SA\|UCB Pharma	Dermatitis, Atopic	March 20, 2002	Phase 3
NCT01000792	Clinical Research International Limited	Allergic Rhinitis	November 2009	Phase 3
NCT00521040	UCB Pharma	Rhinitis, Allergic, Seasonal	February 2004	Not Applicable
NCT00789152	Organon and Co	Allergic Rhinitis	December 1, 2003	Phase 3
NCT02447393	GlaxoSmithKline	Dermatitis	March 18, 2008	Phase 1
NCT03789422	University Hospital, Grenoble	Chronic Spontaneous Urticaria	December 10, 2019	Phase 4
NCT00315523	UCB Pharma	Rhinitis, Allergic, Seasonal	July 2006	Phase 3
NCT00884325	Derm Research, PLLC\|UCB Pharma	Atopic Dermatitis\|Pruritus	February 2009	Phase 4
NCT00525278	UCB Pharma	Rhinitis\|Allergic\|Seasonal	August 2003	Phase 3
NCT01506076	Dr. Reddy´s Laboratories Limited	Fasting	December 2007	Phase 1
NCT00150761	UCB Pharma	Anti-allergic Agents	July 2004	Phase 4
NCT00421109	Faes Farma, S.A.	Urticaria	July 2006	Phase 3
NCT00375713	UCB Pharma	Dermatitis\|Eczema	October 2005	Phase 3
NCT01586091	Charite University, Berlin, Germany	Pruritus\|Chronic Urticaria\|Allergic Rhinitis	February 2011	Phase 4
NCT00653224	UCB Pharma	Seasonal Allergic Rhinitis	April 2008	Phase 4
NCT01622283	GlaxoSmithKline	Rhinitis, Allergic, Perennial and Seasonal	May 2, 2012	Phase 1
NCT01567501	IPCA Laboratories Ltd.	Fed	February 2012	Phase 1
NCT01496911	Utrecht Institute for Pharmaceutical Sciences\|Royal Netherlands Navy	Healthy Volunteers	April 2012	Phase 4
NCT02372604	Hospices Civils de Lyon	Chronic Spontaneous Urticaria	July 2015	Phase 3
NCT05348148	Camillians Saint Mary´s Hospital Luodong	Allergic Rhinitis\|Vasomotor Rhinitis	June 16, 2020	Not Applicable
NCT01491503	Hanmi Pharmaceutical Company Limited	Healthy	November 2011	Phase 1
NCT04399525	Universitaire Ziekenhuizen KU Leuven	Pruritus	October 28, 2019	Not Applicable
NCT01640535	Hanmi Pharmaceutical Company Limited	Perennial Allergic Rhinitis	June 2012	Phase 3
NCT01506063	Dr. Reddy´s Laboratories Limited	Healthy	January 2008	Phase 1
NCT00628108	UCB Pharma	Allergic Rhinitis\|Chronic Urticaria	March 2008	Phase 3
NCT00894231	AAADRS Clinical Research Center\|UCB Pharma	Perennial Allergic Rhinitis	January 2009	Phase 4
NCT00826943	Vanderbilt University	Allergic Rhinitis	January 2009	Phase 4
NCT05565729	Eli Lilly and Company\|Nektar Therapeutics	Healthy	October 5, 2022	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 216.54 mM ; Need ultrasonic)

DMSO : 100 mg/mL ( 216.54 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1654 mL	10.8270 mL	21.6539 mL
5 mM	0.4331 mL	2.1654 mL	4.3308 mL
10 mM	0.2165 mL	1.0827 mL	2.1654 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 50 mg/mL (108.27 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Lohar P, et al. Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. Biomed Chromatogr. 2019 Dec;33(12):e4672.

Synonyms

Acetic acid, 2-[2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2)

Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride, (R)-

Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride

Levocetirizine dihydrochloride

Xusal

Xyzal

Xyzall

UCB 28556

(R)-Cetirizine dihydrochloride

(R)-(-)-Cetirizine hydrochloride

Allercet

Lezyncet

Allear

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart